When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
Multiple Sclerosis International · 2011
DOI: 10.1155/2011/724871 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis International, 2011. Verfasst von Mona Alkhawajah und 1 weiteren Autor:innen. Beteiligte Einrichtung: Multiple Sclerosis Clinic and Neuro-Immunology Laboratory, Department of Medicine, University of British Columbia, Room S-159, 2211 Wesbrook Mall, Va…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
For patients with Relapsing Remitting Multiple Scierosis Beta Interfaerons and Glatiramer Acetate were the first to be licensed for treatment. This review deals with one major question: when to initiate therapy? Through exploring the unique characteristics of the disease and treatement we suggest an approach that should be helpful in the process of decision-making.
Autor:innen und Institutionen
- Multiple Sclerosis Clinic and Neuro-Immunology Laboratory, Department of Medicine, University of British Columbia, Room S-159, 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2H5.
Zitieren
APA
Alkhawajah, M., & Oger, J. (2011). When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?. Multiple Sclerosis International. https://doi.org/10.1155/2011/724871
Vancouver
Alkhawajah M, Oger J. When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?. Multiple Sclerosis International. 2011. doi:10.1155/2011/724871
BibTeX
@article{Alkhawajah2011,
author = {Alkhawajah, Mona and Oger, Joel},
title = {When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?},
journal = {Multiple Sclerosis International},
year = {2011},
doi = {10.1155/2011/724871}
}
EUVIMED